NASDAQ:SCLX Scilex (SCLX) Stock Price, News & Analysis $1.68 -0.02 (-1.18%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.62▼$1.7050-Day Range$1.08▼$2.1552-Week Range$0.73▼$6.55Volume556,274 shsAverage Volume1.09 million shsMarket Capitalization$305.41 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Scilex alerts: Email Address Scilex MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside376.2% Upside$8.00 Price TargetShort InterestHealthy6.98% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 4 Articles This WeekInsider TradingAcquiring Shares$121,521 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.74) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.07 out of 5 starsMedical Sector393rd out of 936 stocksBiological Products, Except Diagnostic Industry55th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingScilex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageScilex has only been the subject of 2 research reports in the past 90 days.Read more about Scilex's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.98% of the float of Scilex has been sold short.Short Interest Ratio / Days to CoverScilex has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Scilex has recently decreased by 7.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldScilex does not currently pay a dividend.Dividend GrowthScilex does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SCLX. Previous Next 2.7 News and Social Media Coverage News SentimentScilex has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Scilex this week, compared to 2 articles on an average week.Search InterestOnly 14 people have searched for SCLX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Scilex insiders have bought more of their company's stock than they have sold. Specifically, they have bought $121,521.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.73% of the stock of Scilex is held by insiders.Percentage Held by Institutions69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Scilex's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Scilex are expected to grow in the coming year, from ($0.74) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Scilex is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scilex is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Scilex's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Scilex Stock (NASDAQ:SCLX)Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.Read More SCLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCLX Stock News HeadlinesJuly 26 at 2:57 AM | americanbankingnews.comScilex (NASDAQ:SCLX) Trading Down 0.6%July 24 at 10:52 AM | globenewswire.comScilex Holding Company Announces Publication of Its Inaugural Sustainability ReportJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 3, 2024 | benzinga.comNon-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ DebutJuly 2, 2024 | globenewswire.comSemnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business CombinationJuly 2, 2024 | globenewswire.comScilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New YorkJune 20, 2024 | globenewswire.comScilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.June 14, 2024 | globenewswire.comScilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)July 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.June 11, 2024 | globenewswire.comScilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio CompaniesJune 11, 2024 | globenewswire.comScilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®June 10, 2024 | globenewswire.comScilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.June 6, 2024 | globenewswire.comScilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024May 30, 2024 | globenewswire.comScilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding CompanyMay 25, 2024 | finance.yahoo.comNews Flash: 3 Analysts Think Scilex Holding Company (NASDAQ:SCLX) Earnings Are Under ThreatMay 24, 2024 | globenewswire.comScilex Holding Company Announces it has been Added to the MSCI Global Microcap IndexMay 24, 2024 | globenewswire.comScilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding CompanyMay 22, 2024 | finance.yahoo.comWith Scilex Holding Up 36%, Insider Buyers Count Their ReturnsSee More Headlines Receive SCLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCLX CUSIPN/A CIK1820190 Webwww.scilexholding.com Phone650-516-4310FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$13.00 Low Stock Price Target$4.00 Potential Upside/Downside+376.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,330,000.00 Net Margins-229.47% Pretax Margin-229.46% Return on EquityN/A Return on Assets-106.29% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.14 Sales & Book Value Annual Sales$46.74 million Price / Sales6.53 Cash FlowN/A Price / Cash FlowN/A Book Value($1.10) per share Price / Book-1.53Miscellaneous Outstanding Shares181,790,000Free Float165,372,000Market Cap$305.41 million OptionableOptionable Beta1.22 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Henry H. Ji Ph.D. (Age 60)Executive Chairman Comp: $885.43kMr. Jaisim Shah (Age 64)President, CEO & Director Comp: $971.52kMr. Stephen Ma (Age 51)Senior VP, CFO & Corporate Secretary Comp: $708.78kDr. Suketu D. Desai Ph.D. (Age 58)CTO & Senior VP Ms. Gigi DeGuzmanExecutive Director of Administrative Operations & Head of Human ResourcesMr. Steven F. Lincoln J.D.General Counsel & Chief Compliance OfficerMr. Sumant RajendranExecutive Director of MarketingMike CiaffiNational Sales DirectorMr. Suresh K. Khemani (Age 64)Senior VP & Chief Commercial Officer Comp: $456.82kDr. Dmitri V. Lissin M.D. (Age 64)Senior VP & Chief Medical Officer Comp: $528.83kMore ExecutivesKey CompetitorsMarketWiseNASDAQ:MKTWCullinan TherapeuticsNASDAQ:CGEMArcutis BiotherapeuticsNASDAQ:ARQTDisc MedicineNASDAQ:IRONCollegium PharmaceuticalNASDAQ:COLLView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 15,815 shares on 7/26/2024Ownership: 0.009%Donald L. Hagan LLCBought 42,245 shares on 7/19/2024Ownership: 0.063%Jay ChunBought 57,500 shares on 5/17/2024Total: $51,750.00 ($0.90/share)Jaisim ShahBought 83,061 shares on 5/16/2024Total: $69,771.24 ($0.84/share)Vanguard Group Inc.Bought 55,757 shares on 5/10/2024Ownership: 2.400%View All Insider TransactionsView All Institutional Transactions SCLX Stock Analysis - Frequently Asked Questions How have SCLX shares performed this year? Scilex's stock was trading at $2.04 on January 1st, 2024. Since then, SCLX stock has decreased by 17.6% and is now trading at $1.68. View the best growth stocks for 2024 here. How were Scilex's earnings last quarter? Scilex Holding (NASDAQ:SCLX) released its quarterly earnings results on Monday, May, 13th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.14. The business earned $10.88 million during the quarter, compared to the consensus estimate of $15.67 million. Who are Scilex's major shareholders? Scilex's top institutional investors include Donald L. Hagan LLC (0.06%) and Bank of New York Mellon Corp (0.01%). Insiders that own company stock include Jay Chun and Jaisim Shah. View institutional ownership trends. How do I buy shares of Scilex? Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SCLX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Please log in to your account or sign up in order to add this asset to your watchlist. Share Scilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.